Publication: EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
Loading...
Date
2020-09-01T00:00:00Z
Authors
Authors
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
ÖZGÜROĞLU, Mustafa
Gogishvili, M.
TÜRK, HACI MEHMET
Cicin, I.
Bentsion, D.
Gladkov, O.
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Description
Keywords
Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31